Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
MedImmune LLC
Bruce A C Cree; Jeffrey L Bennett; Ho Jin Kim; Brian G Weinshenker; Sean J Pittock; Dean M Wingerchuk; Kazuo Fujihara; Friedemann Paul; Gary R Cutter; Romain Marignier; Ari J Green; Orhan Aktas; Hans-Peter Hartung; Fred D Lublin; Jorn Drappa; Gerard Barron; Soraya Madani; John N Ratchford; Dewei She; Daniel Cimbora; Eliezer Katz
Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA.